Insider Purchases: Inside the Buy
Tag: Funanc1al
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
How Many Insider Buys Will It Take for The Bull in Enphase Energy to Re-energize?
After a brutal drop, Enphase Energy’s CEO is buying big. Institutions are all in. Margins hold strong. Could this be the spark the solar bull needs?
Proto Labs (PRLB): The CEO Bought Shares. Should You?
The CEO of Proto Labs just invested in his own company — but it’s not just him. Wall Street giants are in, revenue’s at record levels, and PRLB might be building toward a breakout. Should you 3D-print it into your portfolio?
MSCI Keeps Winning — and the CEO Keeps Buying In
MSCI delivers world-class data tools for investors—and its CEO just bought in big. With soaring revenue, recurring subscriptions, and loyal institutions, is this still a buy? Or has the stock outpaced its fundamentals?
EPD: Enterprise Products Partners Is Boring—But It Pays to Be Boring
Enterprise Products Partners (EPD) might not make headlines, but it makes money. With insiders buying big, a solid 7% dividend, and decades of steady growth, this is one midstream stock that flows cash — not drama.
Insiders Bought "MicroStrategy" Shares at $90. You’re Paying $394.66. Should You?
MSTR insiders are buying, but not the stock you think. They bought STRC at $90 — while MSTR trades near $400. What gives? We break down the numbers, the Bitcoin twist, and what might be worth nibbling on.
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?
Can Elevance Reach Higher Elevations? The CEO Thinks So
📉 After falling nearly 50% from its highs, Elevance Health just got a $2.4M vote of confidence from its CEO. Is this the cure—or just another symptom? 🏥 Dive into the numbers, the risks, and the potential rewards. And yes, there will be icons. 📊💊📈
Healthpeak Properties (DOC): Insiders Are Buying—Should You?
📈 Healthpeak Properties (DOC) insiders are buying—and not just a little. But with a forward P/E north of 70 and a few post-merger integration challenges, is this stock still a hidden gem or more of a polished maybe? Dive in for the full take.
Not Everybody Likes Hunting, But Insiders Preyed On Sportsman's Warehouse's Stock
Sportsman's Warehouse (SPWH) may be wounded, but insiders are on the prowl. With CEO and directors buying stock, and a valuation that screams “cheap,” is this outdoor retailer staging a comeback? Time to load up—or duck?